Edition:
India

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

9.24USD
18 Sep 2020
Change (% chg)

$0.39 (+4.41%)
Prev Close
$8.85
Open
$8.98
Day's High
$9.38
Day's Low
$8.95
Volume
1,336,712
Avg. Vol
315,464
52-wk High
$9.98
52-wk Low
$2.47

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix Q2 Loss Per Share $0.64
Friday, 7 Aug 2020 

Aug 7 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.64.Q2 EARNINGS PER SHARE ESTIMATE $-0.31 -- REFINITIV IBES DATA.AS OF JUNE 30, 2020, COMPANY HAD $84.3 MILLION IN CASH AND CASH EQUIVALENTS VERSUS $48.2 MILLION AT END OF Q1 2020.OCULAR THERAPEUTIX - BELIEVES EXISTING CASH, CASH EQUIVALENTS AS OF JUNE 30 WILL ENABLE CO TO FUND BUSINESS FOR AT LEAST NEXT 12 MONTHS.  Full Article

Ocular Therapeutix Announces Pricing Of Public Offering Of Common Stock
Wednesday, 20 May 2020 

May 20 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.18 MILLION COMMON SHARES PRICED AT $5.50PER SHARE.  Full Article

Ocular Therapeutix Announces Proposed Public Offering Of Common Stock
Wednesday, 20 May 2020 

May 19 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.  Full Article

Ocular Says Entered Amendment To Existing Collaboration, Option And License Agreement With Regeneron
Friday, 15 May 2020 

May 14 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX INC - ON MAY 8 ENTERED INTO AN AMENDMENT TO ITS EXISTING COLLABORATION, OPTION AND LICENSE AGREEMENT WITH REGENERON PHARMACEUTICALS.OCULAR - CO, REGENERON HAVE ADOPTED NEW WORKPLAN TO TRANSITION JOINT EFFORTS TO RESEARCH & DEVELOPMENT OF EXTENDED-DELIVERY FORMULATION OF AFLIBERCEPT.OCULAR THERAPEUTIX INC - IN ADDITION, AMENDMENT PROVIDES FOR MODIFICATION OF TERMS OF OPTION PREVIOUSLY GRANTED TO REGENERON UNDER AGREEMENT.OCULAR THERAPEUTIX INC - AMENDMENT ALSO REVISES TERM AND TERMINATION PROVISIONS OF AGREEMENT.OCULAR THERAPEUTIX INC - ON MAY 13, 2020, COMPANY RECEIVED ADDITIONAL INTERIM DATA REGARDING ITS ONGOING PHASE 1 CLINICAL TRIAL OF OTX-TKI.OCULAR - RECENTLY AMENDED PHASE 1 CLINICAL TRIAL PROTOCOL OF OTX-TKI AND IS ENROLLING A THIRD COHORT OF SUBJECTS TO RECEIVE A HIGHER DOSE OF 600 ΜG.OCULAR - OTX-TKI HAS BEEN GENERALLY WELL TOLERATED & HAS BEEN OBSERVED TO HAVE FAVORABLE SAFETY PROFILE, WITH NO OCULAR SERIOUS ADVERSE EVENTS TO DATE.  Full Article

Ocular Therapeutix™ Reports Q1 2020 Financial Results And Business Update
Friday, 8 May 2020 

May 8 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND BUSINESS UPDATE.Q1 LOSS PER SHARE $0.41.Q1 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.COVID-19 PANDEMIC HAS IMPACTED RECENT DEXTENZA SALES TRENDS.BELIEVES THERE HAS BEEN LIMITED IMPACT FROM COVID-19 TO DATE ON ITS ONGOING CLINICAL PROGRAMS.RESTRICTIONS ON CATARACT SURGERIES DUE TO PANDEMIC SIGNIFICANTLY REDUCED OUR SALES IN LATE MARCH.CURRENT GUIDELINES FROM HEALTH AUTHORITIES WILL SIGNIFICANTLY IMPACT REVENUE IN Q2.  Full Article

Ocular Therapeutix™ Provides Business Update Amid COVID-19 Pandemic
Monday, 13 Apr 2020 

April 13 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ PROVIDES BUSINESS UPDATE AND RESPONSE TO COVID-19 GLOBAL PANDEMIC.OCULAR THERAPEUTIX INC - CLINICAL PROGRAMS REMAIN ON TRACK.OCULAR THERAPEUTIX SAYS "COMPANY IS WELL POSITIONED DESPITE CHALLENGING ECONOMIC CONDITIONS".OCULAR THERAPEUTIX - PHASE 3 TRIAL OF DEXTENZA FOR TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS EXPECTED TO READ OUT THIS QUARTER.OCULAR THERAPEUTIX INC - CYCLOSPORINE INTRACANALICULAR INSERT IS SET TO ENTER CLINIC IN MIDDLE OF 2020.OCULAR THERAPEUTIX INC - ANTICIPATE SUBSTANTIAL CONTINUED WEAKNESS IN CATARACT VOLUMES THROUGHOUT Q2.OCULAR THERAPEUTIX SEES VARIABLE EXPENSE REDUCTIONS & A REBOUND IN CATARACT VOLUMES IN Q3, CO'S CASH RUNWAY SHOULD EXTEND INTO Q1 2021.OCULAR THERAPEUTIX INC - DUE TO ECONOMIC SLOWDOWN, PRELIMINARY Q1 2020 TOTAL NET PRODUCT REVENUE IS EXPECTED TO BE ABOUT $2.6 MILLION.OCULAR THERAPEUTIX INC - PRELIMINARY DEXTENZA NET PRODUCT REVENUE IS ESTIMATED TO HAVE GROWN ABOUT 31% TO $2.1 MILLION FOR Q1 2020.OCULAR THERAPEUTIX INC - COMPANY IS NOT PROVIDING REVENUE GUIDANCE FOR REMAINDER OF 2020.OCULAR THERAPEUTIX - SOME OF POSTPONED CATARACT SURGERIES EXPECTED TO BE RECAPTURED IN H2 OF YEAR, OVERALL VOLUME IS EXPECTED TO BE DOWN.OCULAR THERAPEUTIX SAYS AGREEMENT WITH JEFFERIES WILL ENABLE CO TO FUND PLANNED OPERATING EXPENSES, DEBT SERVICE OBLIGATIONS, CAPEX INTO Q1 OF 2021.  Full Article

Ocular Therapeutix Says Not Providing Revenue Guidance For Remainder Of 2020
Monday, 13 Apr 2020 

April 13 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX - PRELIMINARY Q1 DEXTENZA NET PRODUCT REVENUE ESTIMATED TO HAVE GROWN ABOUT 31% SEQUENTIALLY (NOT YOY) TO $2.1 MILLION.OCULAR THERAPEUTIX™ PROVIDES BUSINESS UPDATE AND RESPONSE TO COVID-19 GLOBAL PANDEMIC.OCULAR THERAPEUTIX INC - CLINICAL PROGRAMS REMAIN ON TRACK.OCULAR THERAPEUTIX SAYS "COMPANY IS WELL POSITIONED DESPITE CHALLENGING ECONOMIC CONDITIONS".OCULAR THERAPEUTIX - PHASE 3 TRIAL OF DEXTENZA FOR TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS EXPECTED TO READ OUT THIS QUARTER.OCULAR THERAPEUTIX INC - CYCLOSPORINE INTRACANALICULAR INSERT IS SET TO ENTER CLINIC IN MIDDLE OF 2020.OCULAR THERAPEUTIX INC - ANTICIPATE SUBSTANTIAL CONTINUED WEAKNESS IN CATARACT VOLUMES THROUGHOUT Q2.OCULAR THERAPEUTIX SEES VARIABLE EXPENSE REDUCTIONS & A REBOUND IN CATARACT VOLUMES IN Q3, CO'S CASH RUNWAY SHOULD EXTEND INTO Q1 2021.OCULAR THERAPEUTIX INC - DUE TO ECONOMIC SLOWDOWN, PRELIMINARY Q1 2020 TOTAL NET PRODUCT REVENUE IS EXPECTED TO BE ABOUT $2.6 MILLION.OCULAR THERAPEUTIX INC - COMPANY IS NOT PROVIDING REVENUE GUIDANCE FOR REMAINDER OF 2020.OCULAR THERAPEUTIX - SOME OF POSTPONED CATARACT SURGERIES EXPECTED TO BE RECAPTURED IN H2 OF YEAR, OVERALL VOLUME IS EXPECTED TO BE DOWN.OCULAR THERAPEUTIX SAYS AGREEMENT WITH JEFFERIES WILL ENABLE CO TO FUND PLANNED OPERATING EXPENSES, DEBT SERVICE OBLIGATIONS, CAPEX INTO Q1 OF 2021.  Full Article

Ocular Therapeutix™ Reports Fourth Quarter And Year End 2019 Financial Results And Business Update
Friday, 13 Mar 2020 

March 12 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q4 LOSS PER SHARE $0.53.Q4 EARNINGS PER SHARE ESTIMATE $-0.45 -- REFINITIV IBES DATA.ANTICIPATES NET PRODUCT REVENUE OF DEXTENZA FOR Q1 OF 2020 WILL BE IN RANGE OF $2.4 MILLION TO $2.6 MILLION.QTRLY TOTAL REVENUE, NET $2.3 MILLION VERSUS $504,000.  Full Article

Ocular Therapeutix Therapy Demonstrates Clinically-Meaningful Reduction in Intraocular Pressure
Friday, 7 Feb 2020 

Feb 7 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ PRESENTS DATA DEMONSTRATING A CLINICALLY-MEANINGFUL REDUCTION IN INTRAOCULAR PRESSURE IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION TREATED WITH OTX-TIC AT GLAUCOMA 360 CONFERENCE.OCULAR THERAPEUTIX- PHASE 1 CLINICAL TRIAL DATA SHOWED CLINICALLY-MEANINGFUL REDUCTION IN IOP FOR UP TO 18 MONTHS IN PATIENTS TREATED WITH SINGLE INSERTION OF OTX-TIC.  Full Article

Ocular Therapeutix Announces Strategic Update And Operational Restructuring
Saturday, 9 Nov 2019 

Nov 8 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX ANNOUNCES STRATEGIC UPDATE AND OPERATIONAL RESTRUCTURING.OCULAR THERAPEUTIX INC - ESTIMATES THAT WILL RECORD COSTS ASSOCIATED WITH RESTRUCTURING OF APPROXIMATELY $0.7 MILLION IN Q4.OCULAR THERAPEUTIX - PLAN EXPECTED TO RESULT IN ESTIMATED $11 MILLION IN ANNUALIZED SAVINGS THROUGH PERSONNEL REDUCTIONS, ABOUT $14 MILLION IN 1-TIME PROGRAM DEFERRALS.OCULAR THERAPEUTIX - SAVINGS ANTICIPATED TO EXTEND CASH RUNWAY THROUGH 2020 END & PROVIDE IMPROVED FINANCIAL POSITION.OCULAR THERAPEUTIX INC - TO ALLOCATE CAPITAL AND RESOURCES TO MAXIMIZE COMMERCIAL OPPORTUNITY OF DEXTENZA.OCULAR THERAPEUTIX - BELIEVES SAVINGS, WITH PROJECTED SALES OF DEXTENZA & CASH TO RESULT IN EXTENSION OF CO'S CURRENT CASH RUNWAY THROUGH Q4 OF 2020.  Full Article

BRIEF-Ocular Therapeutix - Plans To File Application By End Of 2020 To Initiate Clinical Development Of OTX-TKI In U.S.

* OCULAR THERAPEUTIX - PLANS TO FILE AN APPLICATION BY END OF 2020 TO INITIATE CLINICAL DEVELOPMENT OF OTX-TKI IN UNITED STATES Source text for Eikon: [ID: https://bit.ly/3dYxM2E] Further company coverage: